The vaccine rollout and return to form for dividends will contribute to UOB’s recovery over the course of the year, says OCBC Investment Research. 

OCBC Investment Research is maintaining buy on UOB with a raised fair value of $26.30, implying 1.2x price to book ratio.

“Valuations remain reasonable with the share price trading close to book value and offering an attractive risk reward proposition for patient investors,” says OCBC analysts in a Jan 11 note. 


To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook